IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v41y2018i4d10.1007_s40264-017-0625-z.html
   My bibliography  Save this article

Safety of Human Papillomavirus Vaccines: An Updated Review

Author

Listed:
  • Anastasia Phillips

    (The University of Sydney)

  • Cyra Patel

    (National Centre for Immunisation Research and Surveillance, Kids Research Institute, The Sydney Children’s Hospitals Network)

  • Alexis Pillsbury

    (National Centre for Immunisation Research and Surveillance, Kids Research Institute, The Sydney Children’s Hospitals Network)

  • Julia Brotherton

    (National HPV Vaccination Program Register, Victorian Cytology Service
    The University of Melbourne)

  • Kristine Macartney

    (The University of Sydney
    National Centre for Immunisation Research and Surveillance, Kids Research Institute, The Sydney Children’s Hospitals Network)

Abstract

Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71 countries. Unfortunately, uptake has been impacted in some countries by reduced confidence in the safety of the HPV vaccine. In 2013, we published an extensive review demonstrating a reassuring safety profile for bivalent (2vHPV) and quadrivalent (4vHPV) vaccines. A nonavalent (9vHPV) vaccine is now available and HPV immunisation programmes have been extended to males in 11 countries. The aim of this updated narrative review was to examine the evidence on HPV vaccine safety, focusing on the 9vHPV vaccine, special populations and adverse events of special interest (AESI). The previous searches were replicated to identify studies to August 2016, including additional search terms for AESI. We identified 109 studies, including 15 population-based studies in over 2.5 million vaccinated individuals across six countries. All vaccines demonstrated an acceptable safety profile; injection-site reactions were slightly more common for 9vHPV vaccine than for 4vHPV vaccine. There was no consistent evidence of an increased risk of any AESI, including demyelinating syndromes or neurological conditions such as complex regional pain or postural orthostatic tachycardia syndromes. The risk–benefit profile for HPV vaccines remains highly favourable.

Suggested Citation

  • Anastasia Phillips & Cyra Patel & Alexis Pillsbury & Julia Brotherton & Kristine Macartney, 2018. "Safety of Human Papillomavirus Vaccines: An Updated Review," Drug Safety, Springer, vol. 41(4), pages 329-346, April.
    • Handle: RePEc:spr:drugsa:v:41:y:2018:i:4:d:10.1007_s40264-017-0625-z
    DOI: 10.1007/s40264-017-0625-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-017-0625-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-017-0625-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Kazuki Ozawa & Akiyo Hineno & Tomomi Kinoshita & Sakiko Ishihara & Shu-ichi Ikeda, 2017. "Suspected Adverse Effects After Human Papillomavirus Vaccination: A Temporal Relationship Between Vaccine Administration and the Appearance of Symptoms in Japan," Drug Safety, Springer, vol. 40(12), pages 1219-1229, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Rebecca E. Chandler, 2017. "Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?," Drug Safety, Springer, vol. 40(12), pages 1167-1170, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:4:d:10.1007_s40264-017-0625-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.